05.2025 / Press release

Eligo Bioscience Awarded $5 Million in Non-Dilutive Funding from the French Government to Advance Breakthrough Genetic Medicine Platform for Immuno-Dermatology

More →

10.2024 / Press release

Eligo welcomes genetic medicines leader Bobby Gaspar as chair of its board of directors

More →

07.2024 / Press release

Eligo Publishes a Landmark Study in Nature That Unlocks Genome Editing of Bacteria in the Gut

More →

12.2023 / Press release

Eligo Bioscience Raises $30 Million To Write a Novel Chapter for Genetic Medicines

More →

11.2022 / Press release

Key patent issued on Eligo’s gene editing breakthroughs applied to skin disorders

More →

10.2022 / Press release

Eligo Bioscience Receives FDA Orphan Drug Designation (ODD) and Rare Pediatric Disease (RPD) Designation with First-in-class CRISPR-based medicine

More →

09.2022 / Press release

Eligo Bioscience and Kantonsspital St. Gallen announce their strategic alliance to address inflammatory cardiac diseases through in vivo gene editing

More →

06.2022 / Press release

Eligo unlocks next generation of precision genetic medicine with foundational patents granted covering in-situ base editing of the microbiome and presents first-ever animal data at CRISPR 2022 Conference

More →

06.2022 / Article

After 3 years away, BIO marked by first-time handshakes

More →

06.2022 / Article

Gene-Editing the Microbiome: The Limitless Possibilities

More →

06.2021 / Press release

Eligo Presents Preclinical Data Demonstrating for the First Time that Gut Microbiome Modulation via Delivery of CRISPR Nuclease Impacts Disease Progression

More →

03.2021 / Press release

Eligo Bioscience strengthens leadership with the appointment of former GSK R&D Executive, Dr. Hessel, as Chief Scientific Officer

More →

01.2021 / Press release

Eligo Bioscience signs deal with GSK worth up to $224 million

More →

06.2020 / Press release

CARB-X funds Eligo Bioscience to develop CRISPR-based therapeutics derived from bacteriophages to kill superbugs and prevent deadly infections in transplant patients

More →

09.2019 / Press release

Eligo Bioscience strengthens its leadership and development team

More →

05.2019 / Press release

Eligo has been selected by the European Commission as one of the top 1% Science Startups in Europe and received a €2.8M grant for the development of their lead candidate

More →

02.2019 / La Tribune

Eligo’s CEO is listed among the 100 influencers that will are transforming the French economy

More →

10.2018 / Les Echos

Eligo is listed among the 10 French startups shaping the future of Healthcare

More →

04.2018 / French Government

Eligo is a laureate of the Worldwide Innovation Challenge and grabs €1.8M in non-dilutive funding

More →

09.2017 / Press release, TechCrunch, Business Insider, Les Echos, Le Monde, WSJ…

Eligo secures $20M round of funding from Khosla Ventures & Seventure

More →

06.2017 / World Economic Forum

Eligo is selected as a 2017 Technology Pioneer by the World Economic Forum

More →

01.2017 / Forbes

Xavier Duportet, Eligo’s CEO, is selected among the Forbes 30 Under 30 Europe in Science & Healthcare

More →

09.2016 / Agence Nationale de la Recherche

Eligo Bioscience is awarded two highly-selective grants by the French National Research Agency

More →

05.2016 / Press Release

JP Lehner, former Chief Medical Officer at Sanofi, joins Eligo Bioscience’s Board of Directors

More →

07.2015 / Press Release

Eligo closes a €2M seed-funding round with Seventure Partners

More →

02.2015 / Tremplin Entreprises

Eligo is a laureate of the Tremplin Entreprises National Startup Competition

More →